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Abstract
Background: The use of cardiovascular medication for the primary prevention of cardiovascular disease (CVD) is
potentially inappropriate when potential risks outweigh the potential benefits. It is unknown whether deprescribing
preventive cardiovascular medication in patients without a strict indication for such medication is safe and cost-
effective in general practice.
Methods: In this pragmatic cluster randomised controlled non-inferiority trial, we recruited 46 general practices in
the Netherlands. Patients aged 40–70 years who were using antihypertensive and/or lipid-lowering drugs without
CVD and with low risk of future CVD were followed for 2 years. The intervention was an attempt to deprescribe
preventive cardiovascular medication. The primary outcome was the difference in the increase in predicted (10-year)
CVD risk in the per-protocol (PP) population with a non-inferiority margin of 2.5 percentage points. An economic
evaluation was performed in the intention-to-treat (ITT) population. We used multilevel (generalised) linear regression
with multiple imputation of missing data.
Results: Of 1067 participants recruited between 7 November 2012 and 18 February 2014, 72% were female. Overall,
their mean age was 55 years and their mean predicted CVD risk at baseline was 5%. Of 492 participants in the ITT
intervention group, 319 (65%) quit the medication (PP intervention group); 135 (27%) of those participants were still
not taking medication after 2 years. The predicted CVD risk increased by 2.0 percentage points in the PP intervention
group compared to 1.9 percentage points in the usual care group. The difference of 0.1 (95% CI -0.3 to 0.6) fell within
the non-inferiority margin. After 2 years, compared to the usual care group, for the PP intervention group, systolic
blood pressure was 6 mmHg higher, diastolic blood pressure was 4 mmHg higher and total cholesterol and low-
density lipoprotein-cholesterol levels were both 7 mg/dl higher (all P < 0.05). Cost and quality-adjusted life years did
not differ between the groups.
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Conclusions: The results of the ECSTATIC study show that an attempt to deprescribe preventive cardiovascular
medication in low-CVD-risk patients is safe in the short term when blood pressure and cholesterol levels are monitored
after stopping. An attempt to deprescribe medication can be considered, taking patient preferences into consideration.
Trial registration: This study was registered with Dutch trial register on 20 June 2012 (NTR3493).
Keywords: General practice, Preventive medicine, Cardiovascular disease, Antihypertensive agent, Anticholesteremic
agent, Inappropriate prescribing
Background
Cardiovascular disease (CVD) remains a leading cause of
mortality and morbidity worldwide and is associated with a
loss of quality of life and high costs [1, 2]. Physicians use
their clinical judgement as well as clinical practice guidelines
to determine whether treatment with antihypertensive and
lipid-lowering drugs is necessary for individual patients.
Recommendations concerning the initiation of drug treat-
ment in patients with hypertension or hypercholesterolemia,
but without established CVD, are subject to change and are
still under debate. Currently, guideline recommendations
concerning initiation of drug treatment are often based on
composite risk scores [3–7]. However, recommendations to
start medication in previous guidelines used to be based on
single risk factors, such as increased blood pressure or chol-
esterol levels, or diabetes, and thus lacked an integrated ap-
proach to risk management [8–10], which resulted in drug
prescription to patients who are now considered low-CVD-
risk patients. Over time, these evolving recommendations
have resulted in the potentially inappropriate use of anti-
hypertensive and lipid-lowering drugs, namely, when poten-
tial risks (e.g., side effects) outweigh the potential benefits
[11–14]. Although physicians are aware that medication use
in low-CVD-risk patients is of little benefit, fear of negative
consequences and lack of evidence for withdrawal keep
them from stopping the medication [15]. A study investigat-
ing the positive (e.g., quality of life) and negative effects (e.g.,
increase in CVD risk and experiencing inconvenient symp-
toms) of deprescribing preventive cardiovascular medication
in low-CVD-risk patients may improve physicians’ know-
ledge. Depending on the outcome, this may lead to a more
positive or negative attitude towards deprescribing in this
patient population amongst physicians. Therefore, the aim
of the Evaluating Cessation of STatins and Antihypertensive
Treatment In primary Care (ECSTATIC) study was to
evaluate whether an attempt to deprescribe preventive car-
diovascular medication in low-CVD-risk patients using
these medications without indications according to current
guidelines is safe and cost-effective.
Methods
Study design
The ECSTATIC study was designed and carried out as a
cluster randomised non-blinded parallel-group active-
control non-inferiority study, including patients from 46
general practices in the western part of the Netherlands
from 7 November 2012, with a follow-up period lasting
until 20 November 2015 (Dutch Trial Register, NTR3493).
To reduce contamination of the participants in the control
group, the unit of randomisation and analysis was the gen-
eral practice. The primary outcome was the difference in
the increase in the predicted 10-year CVD risk in the 2
years after the first visit. Our choice for a non-inferiority
trial design was based on the expectation that the attempt
to deprescribe preventive cardiovascular medication in
low-CVD-risk patients would increase CVD risk to some
extent, but, at the same time, would lead to fewer side ef-
fects, lower costs and the disutility of daily medication
use, together tipping the risk-benefit ratio into its favour.
The study protocol was approved by the medical ethics
committee of Leiden University Medical Centre. The
study was conducted in accordance with the Declaration
of Helsinki. The study received external funding from
ZonMw, the Netherlands Organisation for Health Re-
search and Development (reference 200320017). The
funder of the study had no role in study design, data col-
lection, data analysis or interpretation to the data.
To avoid allocation bias and imbalance in the number
of general practices allocated to the study groups, we
used computer-generated block randomisation in a 1:1
ratio, with random block sizes consisting of 10 or 12
general practices.
General practices and participants
All general practices in our network were invited. Before
randomisation, general practitioners (GPs) of the practices
selected possibly eligible patients who were 40 to 70 years
old without established CVD and who had been using po-
tentially inappropriate antihypertensive or lipid-lowering
drugs for at least 1 year based on their electronic medical
record (EMR) (Fig. 1). Patients aged below 40 years old or
over 70 years old were excluded because the SCORE
risk function (recalibrated for the Dutch population),
which we used to assess eligibility for inclusion, is avail-
able only for patients aged 40 to 70 years old [4]. Sub-
sequently, the participating general practices were
randomised. GPs sent a written invitation for trial par-
ticipation to their patients who had already been
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declared eligible before randomisation. We used a
complete-double consent design in which informed con-
sent was sought in both the intervention group and usual
care group, mentioning the use of the other comparison
group. To avoid contamination of the usual care group, the
invitation letter sent to the usual care group did not specify
the exact intervention. The letter sent to the intervention
group explained the intervention and mentioned the use of
a control group that was given care as usual [16].
After obtaining informed consent from the patients,
the researchers reassessed the patients for eligibility
using the SCORE risk function recalibrated for the
Dutch population as used in the Dutch guideline for
Cardiovascular Risk Management (Fig. 2) [4]. An over-
view of all patient inclusion and exclusion criteria is
listed in Additional file 1. We assessed the pre-treatment
CVD risk based on current (i.e., at first visit) age, sex
and smoking behaviour (smoking yes/no), in combin-
ation with reported pre-treatment systolic blood pres-
sure (SBP) and total cholesterol/high-density lipoprotein
(HDL)-cholesterol ratio levels in general practice EMRs.
If these values were not available for up to 1 year before
the start of drug treatment, pre-treatment SBP was con-
servatively estimated at 180 mmHg, and low-density
Fig. 1 Trial profile. aThe number of patients who declined to participate did not differ between the intervention and usual care groups after
adjusting for cluster randomisation (P = 0.28). bAt the measurement 3 months after the first visit, 459 participants had complete data available
for calculation of the 10-year CVD risk score. At the measurement 24 months after the first visit, 403 participants had complete data available
for calculation of the 10-year CVD risk score. cAt the measurement 3 months after the first visit, 546 participants had complete data available
for calculation of the 10-year CVD risk score. At the measurement 24 months after the first visit, 499 participants had complete data available
for calculation of the 10-year CVD risk score. dMissing values of (systolic blood pressure and/or total cholesterol/HDL-cholesterol ratio and/or
smoking status) of 88 participants in the intervention group and 76 in the usual care were imputed. One participant in the intervention group
died of an unknown cause without having attempted to have her medication deprescribed and was not included in the analysis. CVD cardiovascular
disease, EMR electronic medical records, FH familial hypercholesterolemia, GP general practitioner, HDL high-density lipoprotein
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lipoprotein (LDL) and high-density lipoprotein (HDL)
cholesterol levels were estimated based on current levels
of total cholesterol, HDL-cholesterol and LDL-cholesterol
measured by local laboratories (Additional file 1).
The Dutch College of General Practitioners provided
us with the underlying algorithm for CVD risk estima-
tion. We used this algorithm to estimate predicted 10-
year CVD risk. All patients willing to participate who
had a predicted low 10-year risk of CVD morbidity and
mortality, without additional risk increasing factors (fur-
ther reported as low CVD risk), i.e., patients for whom
drug treatment was not recommended according to the
Dutch guideline for Cardiovascular Risk Management,
were included in the trial [4].
Interventions
GPs and (when applicable) practice nurses in intervention
practices received a 2-hour workshop providing informa-
tion about the background, the aim and the intervention
of the ECSTATIC study. The workshop was carried out in
Leiden University Medical Centre and led by a GP with a
special interest in cardiovascular risk management and
one of the researchers of this project (CL).
At the first visit, the research nurse advised partici-
pants in the intervention practices to consult their GP to
discuss deprescribing their preventive cardiovascular
medication. For more details about the factors influen-
cing this decision-making process, refer to an earlier
study we performed [17]. When deprescribing was
attempted, GPs followed our predefined deprescribing
guideline for gradual dose reduction and monitoring of
blood pressure and cholesterol levels (Additional file 2).
Furthermore, they were advised to follow the recom-
mendations of the Dutch guideline for cardiovascular
risk for (re-)initiation of medication (Additional file 2).
No intervention was planned for the GPs, practice
nurses and participants in the usual care group.
Outcome measures
For all participants, we aimed for a follow-up period of 2
years. The primary outcome assessed for non-inferiority
was the increase in participants’ predicted 10-year CVD
risk in the 2 years after the first visit. Non-inferiority
would be declared if the upper limit of the 95% confi-
dence interval (CI) of the difference between the mean
increase in CVD risk in the intervention group and the
mean increase in CVD risk in the usual care group was
below + 2.50 percentage points (on an absolute scale).
The non-inferiority margin was set at 2.50 percentage
points, because we believed this difference in the in-
crease in the 10-year CVD risk between the intervention
group and usual care group was clinically acceptable.
Secondary outcomes assessed for superiority were
SBP; diastolic blood pressure (DBP); total cholesterol,
HDL-cholesterol and LDL-cholesterol levels; body mass
index (BMI; body weight in kilograms/height in metres
squared); waist circumference; body weight; smoking be-
haviour; physical activity; fruit and vegetable intake; and
alcohol consumption. These were all assessed at 3
months and 2 years after the first visit. These variables
were assessed as outcomes because we hypothesised that
the intervention could induce lifestyle changes that
could affect these variables. Other secondary outcomes
were the negative effects of deprescribing (in the inter-
vention group) and the side effects of antihypertensive
and lipid-lowering drugs (in the usual care group) re-
ported by GPs during the trial follow-up, and the inci-
dence of CVD, assessed for superiority 2 years after the
first visit.
We performed three post hoc analyses to investigate
differences between the intervention group and the
usual care group after 2 years of follow-up, using a gen-
eralised logistic mixed linear model to assess the relative
risk (RR) of (1) having a mean increase in CVD risk >
2.50 percentage points; (2) having hypertension, defined
by SBP > 140 mmHg and (3) having hypercholesterol-
emia, defined by LDL-cholesterol level > 96.5 mg/dl (=
2.5 mmol/l). We did not adjust for the baseline values to
calculate RR based on the observed odds ratio (OR) [18].
Measurements
Participants were visited at baseline (first visit), after 3
months and after 24 months by trained research nurses
at the general practice of their GP. During these visits,
smoking behaviour was registered, and SBP and DBP
were measured twice with a five-minute interval on the
arm where SBP at baseline was highest after at least five
minutes of seated rest [4] (Omron HEM-907). Addition-
ally, body weight in kilograms (seca 762), height in centi-
metres (seca 213) and waist circumference in
centimetres (seca 201) were measured and registered.
The research nurse registered the total cholesterol,
HDL-cholesterol and LDL-cholesterol values that local
laboratories reported to the general practices.
Fig. 2 Inclusion and exclusion criteria for ECSTATIC trial
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If research nurses measured a mean SBP > 180 mmHg
or registered a total cholesterol level > 308.9 mg/dl (8
mmol/l) or a LDL-cholesterol level > 193.1 mg/dl (5
mmol/l), the participant’s GP was notified.
Two weeks before each visit, participants were asked
prospectively to keep a 7-day diary of their alcohol con-
sumption [19] and to complete questionnaires concern-
ing: (1) ethnicity and education level (only at baseline);
(2) physical activity (short questionnaire to assess
health-enhancing physical activity (SQUASH) [20–22]);
and (3) fruit and vegetable intake (standard nutrition
questionnaire of Dutch common health services [23]).
The research nurse collected and checked the completed
questionnaires during the visit.
At 24 months of follow-up, participants in the inter-
vention group were asked to describe their deprescribing
status of preventive cardiovascular medication by choos-
ing one of five options: (1) currently not using the medica-
tion, (2) currently using fewer or lower doses of the
medications, (3) restarted some medications, (4) restarted
all medications or (5) never stopped or tried to stop. If
participants did not complete the deprescribing status
questionnaire, we used the reported negative effects of
deprescribing by the GP to search for information about
their deprescribing status and the record of the partici-
pants’ deprescribing status completed by the research
nurse during follow-up.
Safety
GPs in the intervention group were asked to report the
negative effects of deprescribing to the researchers dur-
ing the trial follow-up, and GPs in the usual care group
were asked to report the side effects of antihypertensive
and lipid-lowering drugs. Although an assessment of the
negative effects of deprescribing in the control group
would improve the comparison of the safety profile of
the intervention, this was not possible for practical rea-
sons (e.g., to avoid contamination).
The incidence of CVD in participants was determined
using the International Classification of Primary Care
(ICPC) codes for angina pectoris (K74), acute myocardial
infarction (K75), other/chronic ischaemic heart disease
(K76), transient ischaemic attack (K89), cerebrovascular
accident (K90.03), atherosclerosis (K91), vascular claudi-
cation (K92.01) and aortic aneurysm (K99.01), as regis-
tered by the GP in the EMR (standard care) during
follow-up.
Economic evaluation
Costs were estimated in the intention-to-treat (ITT)
population from a societal perspective at the price level
from 2015 [24]. Costs are reported in pounds (based on
purchasing power parities of 8 August 2016). Primary-
care-specific costs included costs for periodically carried
out patient selection (Additional file 3), general practice
consultations, antihypertensive and lipid-lowering drug
use, and cardiovascular-management-related laboratory
measurements; all of these were based on the EMR from
the general practices. Total health-care costs also in-
cluded specialist and physical therapist consultations,
use of home care and hospitalisations, all reported by
the participants in a cost questionnaire with a 3-month
recall period that was administered at 3, 6, 12 and 24
months in the follow-up period (months in between were
interpolated). Cost-effectiveness acceptability curves were
used to relate the difference in costs to the difference in 2-
year quality-adjusted life years (QALYs), as assessed with
the Dutch tariff for the EQ-5D-3L questionnaire [25].
Hypothetically, QALYs would be higher in the interven-
tion group compared to the usual care group because
of the reduction of the burden of daily medication use
and side effects but would be lower because of an in-
crease in the 10-year CVD risk. Acceptability curves
show the probability that the intervention has a better
net benefit (NB =WTP × QALY – Costs) than the usual
care, depending on the willingness to pay (WTP) for
one QALY [26].
The economic evaluation was limited to the 2-year
trial period, because no reliable information is available
to extrapolate the long-term impact on medication use
and the balance between side effects, CVD risk and costs
in this low-risk population.
Statistical analysis
For the sample size calculation, we set the expected dif-
ference in the increase in the 10-year CVD risk at 1.50
percentage points and the standard deviation at 3.5, and
we estimated the number of participating patients per
general practice attempting to have their medication
deprescribed at 10 (per-protocol or PP population) based
on data from a previous study on deprescribing prevent-
ive cardiovascular medication in low-CVD-risk patients
[12]. We assumed an intraclass correlation coefficient of
0.05, taking into account differences between the partici-
pating general practices that could influence study out-
comes. The prespecified non-inferiority margin of 2.50
percentage points was based on both statistical reason-
ing (sample size) and clinical judgement and was set as
the maximum allowed upper limit of the 95% CI (one-
sided alpha of 5%) of the difference in the increase in
the 10-year CVD risk [27]. Assuming that 2/3 of the par-
ticipants would attempt to have their medication depre-
scribed, we estimated that 464 × 1.5 = 696 participants
from 46 general practices needed to undergo randomisa-
tion. Recruitment of general practices was stopped when
46 were included.
During the trial, the proportion of participants
attempting to have their medication deprescribed was
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less than the expected 67% (approximately 55%), while the
number of eligible patients per general practice was higher
than expected. We, therefore, decided to increase the
number of included patients per general practice, allowing
us to decrease the planned one-sided alpha from 5% to
2.5%. At the end of the inclusion period, we again had to
randomly exclude patients from invitation, because the
number of possibly eligible patients per general practice
was even higher than anticipated early in the trial (Fig. 1).
The primary outcome was evaluated in the PP popula-
tion, defined as all patients who were included at the
first visit and were allocated to the usual care group and
all patients who were included at the first visit in the
intervention group who had (attempted to have) their
preventive cardiovascular medication stopped based on
their self-reported deprescribing status. In non-inferiority
trials, an ITT analysis tends to bias towards making the
intervention and usual care look similar. Therefore, we
chose to evaluate the primary outcome in a PP analysis, as
this analysis is more likely to reflect differences between
the two treatments [28]. Secondary outcomes were eva-
luated in the PP population as well. All analyses were re-
peated for the ITT population. The ITT population is
defined as all usual care and intervention group patients
who were included at the first visit. Furthermore, we eva-
luated the primary outcome, SBP, Furthermore, we evalu-
ated the primary outcome, SBP, DBP and LDL-cholesterol
levels in the quitters population, defined as all usual care
group patients and only those intervention group patients
who were able to permanently stop their medication based
on their self-reported deprescribing status. The interven-
tion group patients are defined as the ITT intervention
group. The intervention group patients who had
(attempted to have) their preventive cardiovascular medi-
cation stopped are defined as the PP intervention group
and the intervention group patients who persisted without
cardiovascular medication 2 years after the first visit are
defined as the quitters intervention group.
We used multiple imputations to deal with missing
values of primary and secondary outcomes and predic-
tors in 15 imputation sets [29]. The following baseline
predictors, without any missing values, were used to
build the imputation model: allocation group, sex, age,
SBP, total cholesterol, HDL-cholesterol, and the utility
value of the EQ-5D-3L questionnaire. The clusters were
not included as predictors to avoid instability of the
model. The imputation model for symmetrically distri-
buted continuous variables was based on linear regres-
sion. For skewly distributed continuous variables
(skewness statistic > 1 or < -1), predictive mean matching
was used. The imputation model for dichotomous vari-
ables was based on logistic regression. For missing
values of height at baseline, we used the value reported
at the end of follow-up and vice versa. For age, we
calculated the patient’s age at the median date of the as-
sessments at 24 months of other patients from the same
general practice. One intervention group patient, who
never attempted to have her preventive cardiovascular
medication deprescribed, died of an unknown cause and
was left out of our ITT analyses at 24 months.
To compare continuous and binary outcomes, linear
mixed and generalised (logistic) mixed linear models
were used, respectively, to adjust for cluster randomisa-
tion and baseline values of the outcome that was evalu-
ated. Given the low incidence of CVD, the estimation of
a cluster effect would be unreliable. Therefore, CVD in-
cidence was analysed with Fisher’s exact test. SPSS Sta-
tistics for Windows version 23 was used for all analyses.
Results
A total of 1067 participants from 46 general practices
(16% of the invited general practices) were included be-
tween November 2012 and February 2014 (Fig. 1 and
Table 1). The median follow-up period was 23 months
(range 17 to 32 months), and the intraclass correlation co-
efficient for the primary outcome was < 0.01. The ITT
intervention group consisted of 492 participants. The PP
intervention group consisted of 319 participants (65% of
the ITT intervention group) who had (temporarily) depre-
scribed medication. The quitters intervention group con-
sisted of 135 participants (27% of the ITT intervention
group) who persisted without cardiovascular medication 2
years after the first visit (Fig. 3). At baseline, there were
some differences between the usual care group, and the
PP and ITT intervention groups (Table 1).
Baseline CVD risk in the PP intervention group was
4.7% compared to 5.3% in the 173 intervention group
participants who continued their medication or had un-
known deprescribing status. The total cholesterol/HDL-
cholesterol ratio at baseline was lower in participants
who had (temporarily) deprescribed medication. How-
ever, there was no difference in age, sex, smoking beha-
viour, SBP or LDL-cholesterol levels.
For 15% of the participants, at the end of follow-up
the levels of SBP, total cholesterol/HDL-cholesterol ratio
or smoking behaviour, which are used to determine the
primary outcome, were missing and were imputed.
Primary outcome
The PP analysis showed a 2-year increase in CVD risk in
both the intervention group and usual care group, from
4.7% to 6.7% (+ 2.0 percentage points) and from 5.1% to
7.0% (+ 1.9 percentage points), respectively. The mean
increase in CVD risk was +0.1 percentage points higher
in the deprescribing group, with a 95% CI of -0.3 to 0.6
percentage points, establishing non-inferiority (Fig. 4).
The ITT analysis showed similar results. CVD risk in-
creased from 4.9 to 6.9% (+ 2.0 percentage points) in the
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intervention group, with a mean difference in the in-
crease of 0.1 percentage points (95% CI -0.4 to 0.7).
Secondary outcomes
Figure 5 shows SBP, LDL-cholesterol levels and predicted
10-year CVD risk at the first visit, and 3 and 24 months
after the first visit. At the end of the follow-up, SBP, DBP,
total cholesterol and LDL-cholesterol levels were higher in
the PP intervention group compared to the usual care
group (all P < 0.01, Table 2). Smoking behaviour and BMI
were similar in both groups. Physical activity level, fruit
and vegetable intake, and alcohol consumption were also
similar in both groups. The ITT analysis showed similar
results for the secondary outcomes.
Cardiovascular events and other negative effects
In the usual care group, eight participants developed CVD
during follow-up and zero developed CVD in the PP inter-
vention group (P = 0.03). In the ITT intervention group,
two participants developed CVD (P = 0.12 compared to
the usual care group). CVD incidence could not be identi-
fied in 61 participants because of withdrawn informed
consent (29 in the usual care group, 5 in the PP interven-
tion group and 32 in the ITT intervention group).
Table 1 Baseline characteristics of general practices and participantsa
Characteristic Usual care group PP intervention group ITT intervention group
General practices
No. of general practices 23 23 23
Years of working experience (as GP) of GP – median (range) 14 (4-36) 21 (1-36) 21 (1-36)
Participants
No. of participants 575 319 492
Caucasian – no. (%) 543 (94.4) 297 (93.1) 451 (91.7)
Higher education – no. (%)b 168 (29.2) 124 (38.9)c 180 (36.6)c
10-year CVD risk score for inclusion (%)d 7.0 (± 5.6) 6.5 (± 4.8) 6.7 (± 4.2)
Cardiovascular risk factors
10-year CVD risk score (%)e 5.1 (± 3.7) 4.7 (± 4.0) 4.9 (± 3.7)
Age (years) 54.9 (± 9.2) 54.5 (± 8.0) 54.5 (± 7.8)
Female – no. (%) 420 (73.0) 229 (71.8) 347 (70.5)
Smokers – no. (%) 66 (11.5) 19 (6.0)c 38 (7.7)c
Systolic blood pressure (mmHg) 139.8 (± 16.3) 140.4 (± 17.2) 140.9 (± 20.8)
Total cholesterol/HDL-cholesterol ratio 3.7 (± 1.4) 3.7 (± 1.0) 3.8 (± 1.0)
LDL cholesterol (mg/dl) 126.8 (± 55.1) 126.4 (± 38.8) 127.2 (± 42.5)
Medication use at baseline
Using antihypertensive drugs – no. (%) 479 (83.3) 280 (87.8) 431 (87.6)
Agents acting on the renin-angiotensin system – no. (%) 300 (52.2) 163 (51.1) 276 (56.1)
Diuretics – no. (%) 267 (46.4) 136 (42.6) 216 (43.9)
Beta-blocking agents – no. (%) 154 (26.8) 83 (26.0) 125 (25.4)
Calcium channel blockers – no. (%) 62 (10.8) 37 (11.6) 61 (12.4)
Other antihypertensive drugs – no. (%) 3 (0.5) 1 (0.3) 2 (0.5)
Using antihypertensive drugs from ≥ 2 classes – no. (%) 58 (10.1) 20 (6.3)c 44 (8.9)
Using lipid-lowering drugs – no. (%) 163 (28.3) 65 (20.4)c 105 (21.3)
HMG CoA reductase inhibitors – no. (%) 162 (28.2) 62 (19.4)c 101 (20.5)c
Other lipid-lowering drugs – no. (%) 10 (2.0) 8 (2.5) 11 (2.2)
Using both antihypertensive and lipid-lowering drugs – no. (%) 67 (11.7) 27 (8.5)c 44 (8.9)c
CVD cardiovascular disease, GP general practitioner, HDL high-density lipoprotein, ITT intention-to-treat, LDL low-density lipoprotein, PP per-protocol
aPlus or minus values are means ± standard deviation. All continuous variables were adjusted for cluster randomisation with multilevel linear models
bUniversity (of professional education) level
cP < 0.05 compared to the usual care group
d10-year CVD risk score estimated for inclusion with baseline values of age, sex and smoking behaviour, and pre-treatment systolic blood pressure and pre-
treatment total cholesterol/HDL-cholesterol ratio as if participants did not use preventive cardiovascular medication
e10-year CVD risk score estimated at baseline with baseline values of age, sex, smoking behaviour, systolic blood pressure and total/cholesterol/HDL-
cholesterol ratio
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In the PP intervention group, GPs reported 76 negative
effects because of deprescribing in 42 of 319 participants
(13.2%) (Table 3). Antihypertensive and/or lipid-lowering
drugs were restarted in 34 of these 42 participants. GPs in
the usual care group reported no side effects of antihyper-
tensive or lipid-lowering drugs during follow-up.
Quitters
An analysis of 135 participants who were still not taking
medication 2 years after the first visit (Fig. 3), showed a
2-year increase in CVD risk from 4.3% to 6.6% (+ 2.3
percentage points). This increase was a +0.4 percentage
points higher compared to the usual care group, with a
95% CI of -0.3 to 1.1 percentage points, establishing
non-inferiority. Two years after the first visit, the differ-
ence in SBP between the quitters intervention group and
the usual care group was 10 mmHg (146 vs. 136 mmHg,
respectively). The difference in DBP was 7 mmHg (87
vs. 80 mmHg, respectively) and the difference in LDL-
cholesterol was 13 mg/dl (141 vs. 128 mg/dl, respect-
ively). All were P < 0.01.
The difference in SBP between the 115 participants who
had their antihypertensive drugs deprescribed (Fig. 3)
compared to the 479 participants using antihypertensive
drugs at baseline in the usual care group was 13 mmHg 2
years after the first visit (149 vs. 136 mmHg, respectively,
P < 0.01). The difference in LDL-cholesterol of the 26 par-
ticipants who had their lipid-lowering drugs deprescribed
(Fig. 3) compared to the 163 participants using lipid-
lowering drugs at baseline in the usual care group was 56
mg/dl (178 vs. 122 mg/dl, respectively, P < 0.01).
Individual follow-up
The RR of having a mean increase in CVD risk > 2.5
percentage points after 2 years of follow-up for the PP
intervention group vs. the usual care group was 1.29
(95% CI 1.01 to 1.61, based on a baseline risk of 0.222
and an OR of 1.40). The RR of having SBP > 140 mmHg
and the RR of having a LDL-cholesterol level > 96.5 mg/
dl for the PP intervention group vs. the usual care group
was 1.41 (95% CI 1.18 to 1.64, based on a baseline risk
of 0.372 and an OR of 1.87) and 1.10 (95% CI 1.04 to
1.15, based on a baseline risk of 0.807 and an OR of
1.96), respectively. The ITT analysis showed similar re-
sults for having SBP > 140 mmHg and having LDL-
cholesterol level > 96.5 mg/dl, as the RR and 95% CI in
Fig. 3 Deprescribing status of preventive cardiovascular medication of the 492 participants in the intervention group. ITT intention-to-treat,
PP per-protocol
Fig. 4 Intention-to-treat and per-protocol analysis of the difference in mean increase in predicted 10-year CVD risk. The error bars depict the 95%
CI of the estimated difference in increase of 10-year CVD risk between the usual care and intervention group 2 years after the first visit. aThe PP
analysis includes only the 319 participants in the intervention group who had (temporarily) deprescibed their preventive cardiovascular medication.
CVD cardiovascular disease, CI confidence interval, ITT intention-to-treat, PP per-protocol
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the ITT analysis were comparable to the RR and 95% CI
resulting from the PP analysis. In the ITT analysis, the
RR of having a mean increase in CVD risk was > 2.5 per-
centage points for the PP intervention group vs. the
usual care group was 1.21 (95% CI 0.97 to 1.49).
Economic evaluation
In the first year, intervention costs and GP consultation
costs were higher in the ITT intervention group by £86
per participant (Additional file 3: Table S3, P < 0.01). In
both years, medication costs were lower in the ITT
intervention group by £28 (P < 0.01). Total 2-year
health-care costs and primary-care costs did not differ
between the two groups (P = 1.00 and P = 0.19, respect-
ively). In addition, no difference was found in QALYs (P
= 0.45) (Additional file 3: Table S3). Whether an attempt
to deprescribe preventive cardiovascular medication is
cost-effective depends on how much one is willing to
pay for 1 QALY. Figure S2 in Additional file 3 shows the
probability that an attempt to deprescribe preventive
cardiovascular medication in general practice is cost-
effective compared with usual care. An attempt to
deprescribe preventive cardiovascular medication is 70%
to 80% likely to be cost-effective for a WTP between
£20,000 and £30,000.
Discussion
The ECSTATIC study revealed that an attempt to depre-
scribe preventive cardiovascular medication in patients
in general practice with predicted low 10-year CVD risk
was safe in the short term compared to usual care based
on a minimal difference in the increase in predicted 10-
year CVD risk. After 2 years of follow-up, the mean
blood pressure was 6 mmHg higher, and the total
Fig. 5 Systolic blood pressure, LDL-cholesterol level and predicted 10-year CVD risk over time in the usual care and intervention groups. Measurements
at t = 0 were performed at the first visit. Error bars depict the 95% confidence interval of the mean. CVD cardiovascular disease, ITT intention-to-treat,
LDL low-density lipoprotein, PP per-protocol
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cholesterol and LDL-cholesterol levels were both on
average 7 mg/dl higher compared to usual care in the
intervention group. The risk of having hypertension after
2 years of follow-up was approximately 20% to 60%
higher in the intervention group and the risk of having
hypercholesterolemia was approximately 5% to 15%
compared to the usual care group. Only 27% of partici-
pants persisted without medication 2 years after the first
visit. In the intervention group, 1-year primary-care
costs were higher, but 2-year primary-care costs and
total health-care costs were similar and there was no dif-
ference in QALYs.
Based on our findings, an attempt to deprescribe pre-
ventive cardiovascular medication in low-CVD-risk pa-
tients is safe when blood pressure and cholesterol levels
are monitored after stopping, but it does not improve
the quality of life or reduce health-care costs.
Strengths and weaknesses of this study
Study strengths include the large sample of general prac-
tices and patients, and the pragmatic trial design. Both
of these reflect the results of implementing such an
intervention in daily practice.
The ECSTATIC study was not designed to answer
questions about efficacy, but was designed as a
pragmatic trial to answer the question of whether a
structured deprescribing strategy in low-CVD-risk pa-
tients is (cost-)effective when implemented in general
practice [30]. The pragmatic choice to leave the decision
to deprescribe to the patient and their GP and the
choice to use an active control group may have resulted
in an underestimation of the effect of the intervention
on CVD risk, blood pressure and cholesterol levels [31].
A PP analysis gave information on the potential effects
of an attempt to deprescribe preventive cardiovascular
medication.
The differences at baseline between the intervention
group and the usual care group may be the consequence
of the different invitation letters that both groups re-
ceived. We minimised the effect of these differences by
correcting all analyses (except for the post hoc analyses)
for baseline values.
Our choice to include participants in the trial based on
their predicted 10-year CVD risk was practice-driven. Al-
though current debate questions the use of population-
based prediction models for drug treatment in individ-
uals, these models seem to predict individual CVD risk
better in low risk than in high risk populations [32, 33].
The predicted 10-year CVD risk score is designed to
assess risk while off treatment. However, the
Table 2 Secondary outcomes after 24 monthsa






t = 24 t = 24 P valued t = 24 P valued
Systolic blood pressure (mmHg) 136.0 ± 0.8 142.4 ± 0.9 < 0.01 140.9 ± 0.8 < 0.01
Diastolic blood pressure (mmHg) 80.7 ± 0.5 84.8 ± 0.6 < 0.01 84.2 ± 0.5 < 0.01
Total cholesterol/HDL-cholesterol ratio 3.83 ± 0.04 3.89 ± 0.05 0.22 3.90 ± 0.05 0.35
Total cholesterol (mg/dl)e 210.0 ± 1.4 217.2 ± 1.8 < 0.01 214.1 ± 1.6 0.05
HDL-cholesterol (mg/dl)e 58.4 ± 0.5 59.1 ± 0.6 0.75 58.3 ± 0.5 0.84
LDL-cholesterol (mg/dl)e 128.2 ± 1.3 135.1 ± 1.7 < 0.01 133.1 ± 1.5 0.01
Smokers – no. (%)f 59 (10.3) 18 (5.6) > 0.31 35 (7.1) > 0.25
Body mass index (weigh tin kg/height in metres squared) 28.0 ± 0.1 27.6 ± 0.1 0.26 27.9 ± 0.1 0.57
Body weight (kg) 81.5 ± 0.3 80.4 ± 0.3 0.18 81.1 ± 0.3 0.35
Waist circumference (cm) 96.1 ± 0.4 96.2 ± 0.5 0.54 96.5 ± 0.4 0.53
Physical activity level (minutes per day)g 137 ± 5 127 ± 6 0.18 130 ± 6 0.36
Fruit and vegetable consumption (grams per day) 329 ± 5 335 ± 7 0.41 333 ± 6 0.62
Alcohol consumption (glasses per day) 0.97 ± 0.05 0.90 ± 0.06 0.29 0.87 ± 0.05 0.10
HDL high-density lipoprotein, ITT intention-to-treat, LDL low-density lipoprotein, PP per-protocol
aPlus or minus values are means ± standard error from linear mixed models
bOnly participants who had (temporarily) deprescribed their preventive cardiovascular medication were analysed in the PP intervention group
cOne participant who died of unknown cause during the follow-up without having attempted to have her preventive cardiovascular medication deprescribed was
left out in the analyses at 24 months in the ITT population of the intervention group
dCompared to the usual care group at 24 months
eTo change value to mmol/l, multiply by 38.61033861
fUsing a generalised logistic mixed linear model adjusting for cluster randomisation did not result in a pooled estimate. Therefore, we calculated estimates for the
15 imputation sets and reported the lowest P value in this table
gFor patients < 55 years old, only activities with a metabolic equivalent (MET) score ≥ 4 kcal/kg/hour executed ≥ 60 minutes on one or more days were taken into
account to assess physical activity level [22]. For patients ≥ 55 years old, only activities with a MET-score ≥ 3 kcal/kg/hour executed ≥ 30 minutes on one or more
days were taken into account to assess physical activity level [22]
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predictions of this risk assessment tool are partly based
on cohorts of patients using cardiovascular medication,
justifying its use in our patient population [34]. Add-
itionally, our choice to include participants based on
their 10-year CVD risk was based on the best available
evidence as aggregated in the current Dutch guideline
for Cardiovascular Risk Management. The long-term
incidence of CVD would have been the optimal primary
outcome measure for our trial. However, time and
budgetary restrictions prevented us from using this
endpoint. We would encourage future studies to com-
pare a deprescribing strategy with usual care in low-
CVD-risk patients based on long-term incidence of
CVD.
For 15% of the participants, we had to impute for
missing data to be able to analyse the primary outcome.
This number of missing data points may lead to less reli-
able results. However, we used rigorous imputation
methods to ensure the validity of our data and the preci-
sion of our results [29]. It was hard to verify based on
the EMRs whether a medication was stopped after 2
years of follow-up or whether it was just not yet pre-
scribed again. Therefore, self-reported deprescribing
status seemed more reliable. The self-reported depre-
scribing status may have led to incorrect allocations to
the ITT intervention group, PP intervention group and
the quitters intervention group. However, SBP and LDL-
cholesterol levels in the PP intervention group and the
quitters intervention group were higher than in the ITT
intervention group, suggesting that the allocation was
quite reliable.
Because adequate registration of cardiovascular events
in the EMRs is usual practice and its extraction based
on ICPC codes was protocolised, we believe the lack of
blinding did not prevent objective registration and col-
lection of events.
Comparison with other studies and interpretation
The ECSTATIC study adds to the body of knowledge
concerning preventive cardiovascular drug treatment as
the primary prevention of CVD because of its pragmatic
design. It was carried out in a primary-care population
with low average CVD risk.
The preventive effects of antihypertensive and lipid-
lowering drugs in low-CVD-risk populations are less than
in intermediate-risk and high-risk populations [35–39].
The HOPE-3 investigators found that treatment with 16
mg of candesartan and 12.5 mg of hydrochlorothiazide
per day by intermediate-risk patients did not result in a
significantly lower risk of major cardiovascular events
compared to a placebo [37]. Antihypertensive therapy re-
duced CVD risk only in intermediate-risk patients with
higher baseline SBP (> 143.5 mmHg) [37]. Furthermore,
the meta-analysis of the Cholesterol Treatment Trialist
collaborators found that a statin-induced LDL-cholesterol
reduction of 1 mmol/l (38.6 mg/dl) in patients without
vascular disease with a 5-year major vascular event risk <
5%, did lower the rate ratio of vascular events, though not
the rate ratio of vascular death [35]. The findings of these
studies are consistent with the similar and low incidence
of CVD (although underpowered) in the usual care group
and intervention group and the non-inferiority of an at-
tempt to deprescribe in the ECSTATIC population (which
had a mean SBP of 140 mmHg at baseline, and a mean
10-year CVD risk of 5%).
With a mean 10-year CVD risk of 5%, the ECSTATIC
population has lower risk compared to populations in
other trials. Based on their reports of baseline character-
istics, the study populations of recent trials, such as the
JUPITER Study (approximately 15% 10-year CVD risk),
the HOPE-3 trial (approximately 17% 10-year CVD risk)
and the SPRINT trial (approximately 24% 10-year CVD
risk), have higher risks at baseline, predominantly be-
cause of the higher ages and fewer female participants
[37, 40–43]. The findings from these trials cannot, there-
fore, be directly compared with the ECSTATIC popula-
tion. With a mean 10-year CVD risk of approximately
6%, mean age of 58.3 years and inclusion of 68% women,
the total Asian population in the MEGA Study is most
comparable to the ECSTATIC population [44]. The
Table 3 Negative effects of deprescribing reported to the




participants (n = 34)




Headache or migraine 18 11
Nervous or stressed feeling 7 5
Palpitations 7 5
Ankle oedema or fluid buildup 4 3
Hypercholesterolemia 4 4
Pressure sensation on chest 2 2
Dizziness 2 2
Not feeling well 2 2
Tachycardia 1 1




Hot flushes 1 1
Total 76 61
GP general practitioner
aGPs in the usual care group did not report any side effect of antihypertensive
or lipid-lowering drugs to the researchers during follow-up
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MEGA Study showed that statins reduce the relative risk
of coronary heart disease in a subgroup of patients with
LDL-cholesterol levels > 4.01 mmol/l (155 mg/dl) [44].
This suggests that the 26 ECSTATIC participants who
had their lipid-lowering drugs deprescribed 2 years after
the first visit, with a mean LDL-cholesterol level of 178
mg/dl, may benefit from the preventive effects of statin
use. However, other evidence suggests that the increase
in total life expectancy and CVD-free life expectancy
may be too small to justify long-term statin use at all, es-
pecially in an ageing population [45].
It is remarkable that 35% of the participants in the inter-
vention group of the ECSTATIC study did not attempt to
have their medication deprescribed. Based on the findings
of two of our previous studies, possible reasons for not
doing an attempt are, for example, fear of the conse-
quences of deprescribing, fear of cardiovascular events, the
lack of negative effects of the medication participants ex-
perienced, or the GPs’ doubts about deprescribing [17, 46].
Furthermore, only 27% of the participants in the interven-
tion group persisted in quitting, while 65% of the partici-
pants did attempt to have their medication deprescribed.
Reasons for restarting medication were scarcely reported
by GPs, as reasons were reported in only 34 restarted par-
ticipants (18% of all restarted participants). However,
hypertension, headaches, nervousness and stress, or palpi-
tations were most frequently mentioned by GPs as reasons
for restarting medication.
Conclusions
The results of the ECSTATIC study show that an at-
tempt to deprescribe preventive cardiovascular medica-
tion in patients with predicted low CVD risk is safe in
the short term, but does not necessarily improve quality
of life or reduce health-care costs. Moreover, less than
one third of participants persisted without cardiovascu-
lar medication after 2 years of follow-up. Therefore, we
do not recommend implementation of a structured
deprescribing strategy for all patients with low CVD risk
in general practice as was implemented in the interven-
tion group of the ECSTATIC study.
However, an attempt to deprescribe may be considered
in low-CVD-risk patients, e.g., during their routine
(yearly) cardiovascular check-up and as the result of a
shared decision between a doctor and their patient. In
an earlier study, we found that low-CVD-risk patients
and their GPs may doubt the appropriateness of medica-
tion use, fear side effects, dislike medication use and
consider alternative prevention options [17]. Although
an attempt to deprescribe medication increases the risk
of developing hypertension by approximately 20% to
60% and the risk of developing hypercholesterolemia by
approximately 5% to 15%, the balance of the risks of (fu-
ture) side effects and benefits for individual patients
(e.g., no burden of daily medication use), together with
patients’ preferences, may drift in the direction of an in-
dividual attempt to deprescribe medication. When an
attempt to deprescribe preventive cardiovascular medi-
cation in low-CVD-risk patients is made, it is important
to monitor blood pressure and cholesterol levels, espe-
cially in the first 3 months after withdrawal, and to as-
sess whether drug treatment should be re-initiated.
Combining deprescribing with a lifestyle intervention
could possibly restrict increases in blood pressure and
cholesterol levels and lower CVD risk [47–49].
In conclusion, a structured deprescribing strategy for
all patients with low CVD risk in general practice is not
recommended because of its low adherence (27% per-
sistent quitters) and low gains in quality of life, but an
attempt to deprescribe for those willing to is safe in the
short term when blood pressure and cholesterol levels
are monitored after stopping and can therefore, be con-
sidered in low-CVD-risk patients during routine visits.
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